Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis

Ellen Westhoff, J Alfred Witjes, Neil E Fleshner, Seth P Lerner, Shahrokh F Shariat, Gunnar Steineck, Ellen Kampman, Lambertus A Kiemeney, Alina Vrieling, Ellen Westhoff, J Alfred Witjes, Neil E Fleshner, Seth P Lerner, Shahrokh F Shariat, Gunnar Steineck, Ellen Kampman, Lambertus A Kiemeney, Alina Vrieling

Abstract

Background: Urologists are frequently confronted with questions of urinary bladder cancer (UBC) patients about what they can do to improve their prognosis. Unfortunately, it is largely unknown which lifestyle factors can influence prognosis.

Objective: To systematically review the available evidence on the association between body mass index (BMI), diet, dietary supplements, and physical activity and UBC prognosis.

Methods: We searched PubMed and Embase up to May 2017. We included thirty-one articles reporting on observational and randomized controlled trials investigating BMI, diet and dietary supplements in relation to recurrence, progression, cancer-specific or all-cause mortality in UBC patients.

Results: In non-muscle invasive bladder cancer (NMIBC) patients, both overweight (3 studies, pooled hazard ratio (HR) 1.29, 95% CI 1.05-1.58, I2 = 0%) as well as obesity (3 studies, pooled HR 1.82, 95% CI 1.12-2.95, I2 = 79%) were associated with increased risk of recurrence when compared to normal weight. No association of BMI with risk of progression was found. Results for BMI and prognosis in muscle-invasive or in all stages series were inconsistent. Observational studies on diet and randomized controlled trials with dietary supplements showed inconsistent results. No studies on physical activity and UBC prognosis have been published to date.

Conclusions: Evidence for an association of lifestyle factors with UBC prognosis is limited, with some evidence for an association of BMI with risk of recurrence in NMIBC. Well-designed, prospective studies are needed to develop evidence-based guidelines on this topic.

Keywords: Body mass index; diet; dietary supplements; prognosis; urinary bladder cancer.

Figures

Fig.1
Fig.1
PRISMA flow diagram for the study selection process.
Fig.2
Fig.2
BMI and NMIBC prognosis: (A) Overweight vs. normal weight and risk of recurrence; (B) Obesity vs. normal weight and risk of recurrence; (C) Overweight vs. normal weight and risk of progressoin; (D) Obesity vs. normal weight and risk of progression.
Fig.3
Fig.3
BMI and prognosis in all stages series: (A) Overweight vs. normal weight and risk of recurrence; (B) Obesity vs. normal weight and risk of recurrence; (C) Overweight vs. normal weight and risk of CSM; (D) Obesity vs. normal weight and risk of CSM.

References

    1. Ligibel J. Lifestyle factors in cancer survivorship. Journal of Clinical Oncology 2012;30(30):3697–704.
    1. Hou L, Hong X, Dai M, Chen P, Zhao H, Wei Q, et al. Association of smoking status with prognosis in bladder cancer: A meta-analysis. Oncotarget 2017;8(1):1278–89.
    1. Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, Shariat SF. Effect of smoking on outcomes of urothelial carcinoma: A systematic review of the literature. European Urology 2014;65(4):742–54.
    1. Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines: Non-muscle-invasive bladder cancer. BJU International 2017;119(3):371–80.
    1. Kluth LA, Xylinas E, Crivelli JJ, Passoni N, Comploj E, Pycha A, et al. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. Journal of Urology 2013;190(2):480–6.
    1. Maurer T, Maurer J, Retz M, Paul R, Zantl N, Gschwend JE, et al. Influence of body mass index on operability, morbidity and disease outcome following radical cystectomy. Urologia Internationalis 2009;82(4):432–9.
    1. Ros MM, Bueno-de-Mesquita HB, Kampman E, Aben KK, Buchner FL, Jansen EH, et al. Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. The American Journal of Clinical Nutrition 2012;96(4):902–10.
    1. Silberstein JL, Parsons JK. Evidence-based principles of bladder cancer and diet. Urology 2010;75(2):340–6.
    1. Donat SM, Bayuga S, Herr HW, Berwick M. Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer. Journal of Urology 2003;170(5):1777–80.
    1. Ros MM, Bas Bueno-de-Mesquita HB, Buchner FL, Aben KK, Kampman E, Egevad L, et al. Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC). International Journal of Cancer 2011;128(11):2695–708.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. International Journal of Surgery 2010;8(5):336–41.
    1. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre TCC, 2014.
    1. Alfthan O, Tarkkanen J, Grohn P, Heinonen E, Pyrhonen S, Saila K. Tigason (etretinate) in prevention of recurrence of superficial bladder tumors. A double-blind clinical trial. European Urology 1983;9(1):6–9.
    1. Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. European Urology 1995;27(2):104–9.
    1. Aso Y, Akazan H. Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. BLP Study Group Urologia Internationalis 1992;49(3):125–9.
    1. Bachir BG, Aprikian AG, Izawa JI, Chin JL, Fradet Y, Fairey A, et al. Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: Results from a Canadian multicenter collaboration. Urologic Oncology 2014;32(4):441–8.
    1. Byar D, Blackard C, Christeson WW. Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology 1977;10(6):556–61.
    1. Chromecki TF, Cha EK, Fajkovic H, Rink M, Ehdaie B, Svatek RS, et al. Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. BJU International 2013;111(2):249–55.
    1. Dabi Y, Rouscoff Y, Anract J, Delongchamps NB, Sibony M, Saighi D, et al. Impact of body mass index on the oncological outcomes of patients treated with radical cystectomy for muscle-invasive bladder cancer. World Journal of Urology 2017;35(2):229–235.
    1. Decensi A, Torrisi R, Bruno S, Costantini M, Curotto A, Nicolo G, et al. Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point. Cancer Epidemiology Biomarkers and Prevention 2000;9(10):1071–8.
    1. Goossens ME, Zeegers MP, van Poppel H, Joniau S, Ackaert K, Ameye F, et al. Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial. European Journal of Cancer 2016;69:9–18.
    1. Hafron J, Mitra N, Dalbagni G, Bochner B, Herr H, Donat SM. Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer? Journal of Urology 2005;173(5):1513–7.
    1. Kwon T, Jeong IG, You D, Han KS, Hong S, Hong B, et al. Obesity and prognosis in muscle-invasive bladder cancer: The continuing controversy. International Journal of Urology 2014;21(11):1106–12.
    1. Lamm DL, Riggs DR, Shriver JS, VanGilder PF, Rach JF, DeHaven JI. Megadose vitamins in bladder cancer: A double-blind clinical trial. Journal of Urology 1994;151(1):21–6.
    1. Leiter A, Doucette J, Krege S, Lin CC, Hahn N, Ecke T, et al. Obesity and outcomes in patients with metastatic urothelial carcinoma. Bladder Cancer 2016;2(3):341–9.
    1. Mazdak H, Zia H. Vitamin E reduces superficial bladder cancer recurrence: A randomized controlled trial. International Journal of Preventive Medicine 2012;3(2):110–5.
    1. Michalek AM, Cummings KM, Phelan J. Vitamin A and tumor recurrence in bladder cancer. Nutrition and Cancer 1987;9(2-3):143–6.
    1. Naito S, Koga H, Yamaguchi A, Fujimoto N, Hasui Y, Kuramoto H, et al. Prevention of recurrence with epirubicin and Lactobacillus casei after transurethral resection of bladder cancer. Journal of Urology 2008;179(2):485–90.
    1. Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, et al. Nomogram-based prediction of overall survival in patients with metastatic urothelial carcinoma receiving first-line platinum-based chemotherapy: Retrospective international study of invasive/advanced cancer of the urothelium (RISC). European Urology 2017;71(2):281–9.
    1. Nepple KG, Lightfoot AJ, Rosevear HM, O’Donnell MA, Lamm DL. Bacillus Calmette-Gurein with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. Journal of Urology 2010;184(5):1915–9.
    1. Newling DWW, Robinson MRG, Smith PH, Byar D, Lockwood R, Stevens I, et al. Tryptophan metabolites, pyridoxine (Vitamin B6) and their influence on the recurrence rate of superficial bladder cancer: Results of a prospective, randomised phase III study performed by the EORTC GU group. European Urology 1995;27(2):110–6.
    1. Pedersen H, Wolf H, Jensen SK. Administration of a retinoid as prophylaxis of recurrent non-invasive bladder tumors. Scandinavian Journal of Urology and Nephrology 1984;18(2):121–3.
    1. Psutka SP, Boorjian SA, Moynagh MR, Schmit GD, Frank I, Carrasco A, et al. Mortality after radical cystectomy: Impact of obesity versus adiposity after adjusting for skeletal muscle wasting. The Journal of Urology 2015;193(5):1507–13.
    1. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, et al. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clinical Cancer Research 2008;14(1):224–9.
    1. Studer UE, Jenzer S, Biedermann C, Chollet D, Kraft R, Von Toggenburg H, et al. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. European Urology 1995;28(4):284–90.
    1. Tang L, Zirpoli GR, Guru K, Moysich KB, Zhang Y, Ambrosone CB, et al. Intake of cruciferous vegetables modifies bladder cancer survival. Cancer Epidemiology Biomarkers and Prevention 2010;19(7):1806–11.
    1. Wakai K, Ohno Y, Obata K, Aoki K. Prognostic significance of selected lifestyle factors in urinary bladder cancer. Japanese Journal of Cancer Research 1993;84(12):1223–9.
    1. Wyszynski A, Tanyos SA, Rees JR, Marsit CJ, Kelsey KT, Schned AR, et al. Body mass and smoking are modifiable risk factors for recurrent bladder cancer. Cancer 2014;120(3):408–14.
    1. Xu T, Zhu Z, Wang X, Xia L, Zhang X, Zhong S, et al. Impact of body mass on recurrence and progression in Chinese patients with Ta, T1 urothelial bladder cancer. International Urology and Nephrology 2015;47(7):1135–41.
    1. Xu X, Zhou L, Miao R, Chen W, Zhou Y, Pang Q, et al. Association of cancer mortality with postdiagnosis overweight and obesity using body mass index. Oncotarget 2016;7(4):5023–9.
    1. Aso Y, Akazan H. Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. Urologia Internationalis 1992;49(3):125–9.
    1. Hopkins BD, Goncalves MD, Cantley LC. Obesity and Cancer Mechanisms: Cancer Metabolism. Journal of Clinical Oncology 2016;34(35):4277–83.
    1. Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA. Obesity and cancer mechanisms: Tumor microenvironment and inflammation. Journal of Clinical Oncology 2016;34(35):4270–6.
    1. Mbeutcha A, Shariat SF, Rieken M, Rink M, Xylinas E, Seitz C, et al. Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. Urologic Oncology 2016;34(11):483.e17–e24.
    1. Jiang Q. Natural forms of vitamin E: Metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radical Biology & Medicine 2014;72:76–90.
    1. Prasad S, Phromnoi K, Yadav VR, Chaturvedi MM, Aggarwal BB. Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer. Planta Medica 2010;76(11):1044–63.
    1. Kim YS, Farrar W, Colburn NH, Milner JA. Cancer stem cells: Potential target for bioactive food components. The Journal of Nutritional Biochemistry 2012;23(7):691–8.
    1. Van der Heijden AG, Witjes JA. Recurrence, progression, and follow-up in non-muscle-invasive bladder cancer. European Urology Supplements 2009;8:556–62.
    1. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, et al. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. The American Journal of Clinical Nutrition 1995;62(6 Suppl):1427s–30s.
    1. Le Gal K, Ibrahim MX, Wiel C, Sayin VI, Akula MK, Karlsson C, et al. Antioxidants can increase melanoma metastasis in mice. Science Translational Medicine 2015;7(308):308re8.
    1. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO. Antioxidants accelerate lung cancer progression in mice. Science Translational Medicine 2014;6(221):221ra15.
    1. Westerlund A, Steineck G, Balter K, Stattin P, Gronberg H, Hedelin M. Dietary supplement use patterns in men with prostate cancer: The Cancer Prostate Sweden study. Annals of Oncology 2011;22(4):967–72.
    1. World Cancer Research Fund / American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington DC: AICR, 2007.
    1. Sjodahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S, et al. A molecular taxonomy for urothelial carcinoma. Clinical Cancer Research 2012;18(12):3377–86.
    1. Bigley AB, Spielmann G, LaVoy EC, Simpson RJ. Can exercise-related improvements in immunity influence cancer prevention and prognosis in the elderly? Maturitas 2013;76(1):51–6.
    1. Steel JL, Bress K, Popichak L, Evans JS, Savkova A, Biala M, et al. A systematic review of randomized controlled trials testing the efficacy of psychosocial interventions for gastrointestinal cancers. J Gastrointestinal Cancer 2014;45(2):181–9.
    1. Fukushima H, Yokoyama M, Nakanishi Y, Tobisu K, Koga F. Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma. PLoS One 2015;10(1):e0115895.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere